Alnylam Clinical Trial Update – ASG Webinar 4/11
ASG’s Northeastern regional webinar on ATTR amyloidosis, recorded on July 10, 2021. The webinar is presented by: Gabriela Tamariz, MD, Medical Science Liaison, TTR Program, Alnylam Pharmaceuticals.
Webinar
Alkylating Agents – ASG Webinar 2/13
Amyloidosis Support Groups’ webinar for light chain (AL) amyloidosis patients and caregivers in the Northeast region on September 18, 2021. Led by ASG President Muriel Finkel, this webinar discusses the current treatments for light chain amyloidosis and features amyloidosis expert: Cara Rosenbaum, MD, Hematologist/Oncologist and Assistant Professor of Medicine, Weill Cornell Medical College, New York, …
Survival Benefit of Birtamimab in Treating AL Amyloidosis
Morie Gertz, MD, Hematologist, Chair Emeritus Internal Medicine, Mayo Clinic, discusses post hoc analysis data on the survival benefit of birtamimab in high-risk amyloid light chain (AL) amyloidosis in the phase 3 VITAL study. These data were recently presented at the American Society of Hematology Meeting & Exposition (ASH 2022).